MCID: HMG002
MIFTS: 52

Hemoglobinuria

Categories: Immune diseases, Blood diseases, Nephrological diseases

Aliases & Classifications for Hemoglobinuria

Summaries for Hemoglobinuria

MalaCards based summary : Hemoglobinuria is related to hemolytic anemia and myelodysplastic syndrome, and has symptoms including chyluria and other and unspecified genitourinary symptoms. An important gene associated with Hemoglobinuria is PIGA (Phosphatidylinositol Glycan Anchor Biosynthesis Class A), and among its related pathways/superpathways are Innate Immune System and Toxoplasmosis. The drugs Lenograstim and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotype is hematopoietic system.

Wikipedia : 76 In medicine, hemoglobinuria or haemoglobinuria is a condition in which the oxygen transport protein... more...

Related Diseases for Hemoglobinuria

Diseases related to Hemoglobinuria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 151)
# Related Disease Score Top Affiliating Genes
1 hemolytic anemia 30.1 CD55 CD59 HP PIGA
2 myelodysplastic syndrome 29.7 CD55 CD59 CR1 PIGA
3 anemia, autoimmune hemolytic 29.5 C3 CD55 CD59 HP
4 paroxysmal nocturnal hemoglobinuria 29.3 C5 CD14 CD55 CD58 CD59 FCGR3B
5 paroxysmal cold hemoglobinuria 12.4
6 paroxysmal nocturnal hemoglobinuria 1 12.3
7 paroxysmal nocturnal hemoglobinuria 2 12.3
8 aplastic anemia 11.3
9 blackwater fever 11.2
10 blood group, globoside system 10.9
11 warm antibody hemolytic anemia 10.9
12 multiple congenital anomalies-hypotonia-seizures syndrome 10.7 PIGA PIGT
13 acute hemorrhagic conjunctivitis 10.6 C5 CD55
14 multiple congenital anomalies-hypotonia-seizures syndrome 2 10.4 CD55 CD59 PIGA
15 perforated corneal ulcer 10.4 PLAU PLAUR
16 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.4
17 acquired angioedema 10.4 C3 HP
18 multiple congenital anomalies-hypotonia-seizures syndrome 3 10.4 CD55 CD59 PIGT
19 dense deposit disease 10.4 C3 C5
20 thrombosis 10.4
21 ureter, cancer of 10.3 PLAU PLAUR
22 autoimmune disease of blood 10.2 C3 HP
23 budd-chiari syndrome 10.2
24 complement deficiency 10.2 C3 C5
25 leukemia 10.2
26 hemoglobinemia 10.1
27 cerebritis 10.1
28 complement factor i deficiency 10.1 C3 CR1
29 thrombocytopenia 10.1
30 hematopoietic stem cell transplantation 10.0
31 thrombophilia due to thrombin defect 10.0
32 hepatitis 9.9
33 purpura 9.9
34 lymphoma 9.9
35 retinitis 9.9
36 heparin-induced thrombocytopenia 9.9
37 neutropenia 9.9
38 hemosiderosis 9.9
39 dirofilariasis 9.8 HP MB
40 proliferative glomerulonephritis 9.8 C3 CR1
41 myelofibrosis 9.8
42 myeloma, multiple 9.8
43 aging 9.8
44 pancytopenia 9.8
45 myeloid leukemia 9.8
46 fasciitis 9.8
47 inherited bone marrow failure syndromes 9.8
48 paranasal sinus disease 9.7 PLAU PLAUR
49 adamantinoma of long bones 9.7 CD58 PLAU PLAUR
50 leukemia, chronic lymphocytic 2 9.7

Graphical network of the top 20 diseases related to Hemoglobinuria:



Diseases related to Hemoglobinuria

Symptoms & Phenotypes for Hemoglobinuria

UMLS symptoms related to Hemoglobinuria:


chyluria, other and unspecified genitourinary symptoms

MGI Mouse Phenotypes related to Hemoglobinuria:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.32 C3 CD14 CD55 CD59 FCGR3B HP

Drugs & Therapeutics for Hemoglobinuria

Drugs for Hemoglobinuria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 2,Not Applicable 135968-09-1
2
Benzocaine Approved, Investigational Phase 4,Phase 2 1994-09-7, 94-09-7 2337
3
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
4 tannic acid Approved, Nutraceutical Phase 4,Phase 2
5 Cyclosporins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7
Cyclophosphamide Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
8
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
9
Fludarabine Approved Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 21679-14-1, 75607-67-9 30751
10
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
11
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
12
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1 52-24-4 5453
13
Iodine Approved, Investigational Phase 3 7553-56-2 807
14 Alkylating Agents Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
15 Antilymphocyte Serum Phase 3,Phase 2,Not Applicable
16 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antineoplastic Agents, Alkylating Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
18 Muromonab-CD3 Phase 3,Phase 2
19 diuretics Phase 3
20 Natriuretic Agents Phase 3
21 Complement Inactivating Agents Phase 3,Phase 1,Phase 2
22 Complement System Proteins Phase 3,Phase 2,Phase 1
23 Antibodies Phase 3,Phase 2,Not Applicable
24 Immunoglobulins Phase 3,Phase 2,Not Applicable
25 Antimetabolites Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
26 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
27
Nandrolone decanoate Approved, Illicit Phase 1, Phase 2 360-70-3 9677
28
alemtuzumab Approved, Investigational Phase 2,Phase 1,Not Applicable,Early Phase 1 216503-57-0
29
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
30
Melphalan Approved Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 4053 460612
31
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 1, Phase 2 62-90-8 229455
32
Vidarabine Approved, Investigational Phase 1, Phase 2,Phase 2,Early Phase 1,Not Applicable 24356-66-9 32326 21704
33
Mechlorethamine Approved, Investigational Phase 2,Not Applicable 51-75-2 4033
34
Basiliximab Approved, Investigational Phase 2 152923-56-3, 179045-86-4
35
Busulfan Approved, Investigational Phase 2,Not Applicable,Early Phase 1 55-98-1 2478
36
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
37
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
38
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
39
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
40
Etoposide Approved Phase 2,Not Applicable 33419-42-0 36462
41
Abatacept Approved Phase 1, Phase 2 332348-12-6 10237
42
Hydroxyurea Approved Phase 1, Phase 2,Phase 2 127-07-1 3657
43
Mesna Approved, Investigational Phase 2 3375-50-6 598
44
Everolimus Approved Phase 2 159351-69-6 6442177
45
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
46
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
47
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
48
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
49
Nandrolone Experimental, Investigational Phase 1, Phase 2 434-22-0 9904
50
Treosulfan Investigational Phase 2 299-75-2 9296

Interventional clinical trials:

(show top 50) (show all 114)
# Name Status NCT ID Phase Drugs
1 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
2 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
3 Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects Completed NCT00867932 Phase 4 Eculizumab
4 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Unknown status NCT02393508 Phase 3
5 Transfusion Requirements in Critically Ill Oncologic Patient Unknown status NCT01648946 Phase 3
6 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed NCT00098280 Phase 3 Eculizumab
7 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed NCT00130000 Phase 3 Eculizumab
8 Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria Completed NCT00112983 Phase 3
9 Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed NCT00122317 Phase 3 eculizumab
10 Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Completed NCT00122330 Phase 3 eculizumab
11 Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab Completed NCT00122304 Phase 3 eculizumab
12 Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00152139 Phase 3 Chemotherapy and antibodies
13 Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies Completed NCT00186823 Phase 3 TBI, systemic chemotherapy and antibodies as follows:
14 Comparison of Cy-Atg Vs Cy-Flu-Atg for the Conditioning Therapy in Allo-HCT Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
15 Transfusion-requirements in Septic Shock Trial Completed NCT01485315 Phase 3
16 A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03406507 Phase 3
17 ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Active, not recruiting NCT02946463 Phase 3
18 ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Active, not recruiting NCT03056040 Phase 3
19 Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH Not yet recruiting NCT03500549 Phase 3 APL-2;Soliris
20 Multi-center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) Not yet recruiting NCT03531255 Phase 3 APL-2
21 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
22 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
23 An Open Label Study of the Effects of Eculizumab in CD59 Deficiency Unknown status NCT01579838 Phase 1, Phase 2 Eculizumab
24 Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Unknown status NCT01757145 Phase 2 Eltrombopag
25 Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow Failure Unknown status NCT00895739 Phase 2 cyclosporine
26 Nandrolone Decanoate in the Treatment of Telomeropathies Unknown status NCT02055456 Phase 1, Phase 2 Nandrolone Decanoate
27 Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) Completed NCT02591862 Phase 2 Coversin
28 Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT01192399 Phase 2
29 E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients Completed NCT01194804 Phase 2 Eculizumab
30 A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH Completed NCT02352493 Phase 1, Phase 2 ALN-CC5;Sterile Normal Saline (0.9% NaCl)
31 Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia Completed NCT00065260 Phase 2 Campath-1H;r-ATG;CsA
32 Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Completed NCT00975975 Phase 2 Basiliximab
33 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed NCT01187017 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
34 Donor Stem Cell Transplant After Busulfan, Fludarabine, Methylprednisolone, and Antithymocyte Globulin in Treating Patients With Bone Marrow Failure Syndrome Completed NCT00731328 Phase 2
35 Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors Completed NCT00618969 Phase 2
36 Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
37 Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders Completed NCT00587054 Phase 2 cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant
38 Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Completed NCT00997386 Phase 2 busulfan, and melphalan, and alemtuzumab
39 Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies Completed NCT00143559 Phase 2 Systematic chemotherapy and antibodies
40 Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies Completed NCT00145613 Phase 2 Systemic chemotherapy and antibodies
41 Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases Completed NCT02277639 Phase 2
42 Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
43 Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03439839 Phase 2 LNP023
44 A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03053102 Phase 2 ACH-0144471
45 A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Inadequate Response to Eculizumab Recruiting NCT03472885 Phase 2 ACH-0144471;Eculizumab
46 Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria Recruiting NCT02534909 Phase 2
47 Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms Recruiting NCT03427060 Phase 2 Coversin
48 A Long-term Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Recruiting NCT03181633 Phase 2 ACH-0144471
49 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
50 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells Recruiting NCT01174108 Phase 2

Search NIH Clinical Center for Hemoglobinuria

Cochrane evidence based reviews: hemoglobinuria

Genetic Tests for Hemoglobinuria

Genetic tests related to Hemoglobinuria:

# Genetic test Affiliating Genes
1 Hemoglobinuria 29

Anatomical Context for Hemoglobinuria

MalaCards organs/tissues related to Hemoglobinuria:

41
Bone, Bone Marrow, T Cells, Kidney, Testes, Myeloid, Neutrophil

Publications for Hemoglobinuria

Articles related to Hemoglobinuria:

(show top 50) (show all 886)
# Title Authors Year
1
Successful reduced-intensity conditioning hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria with aplastic anemia in two children. ( 29722478 )
2018
2
Microangiopathy and acute kidney injury in paroxysmal cold hemoglobinuria: A challenge for management. ( 29341234 )
2018
3
Maintenance of renal function in a patient with a history of acute paroxysmal nocturnal hemoglobinuria-associated kidney injury. ( 29527312 )
2018
4
Evolutionary dynamics of paroxysmal nocturnal hemoglobinuria. ( 29912864 )
2018
5
Paroxysmal nocturnal hemoglobinuria: Kidney biopsy and magnetic resonance imaging. ( 29629284 )
2018
6
High sensitivity 8-color flow cytometry assay for paroxysmal nocturnal hemoglobinuria granulocyte and monocyte detections. ( 29599976 )
2018
7
Proteinase 3 expression on the neutrophils of patients with paroxysmal nocturnal hemoglobinuria. ( 29467851 )
2018
8
The prothrombotic state in paroxysmal nocturnal hemoglobinuria: a multifaceted source. ( 29246924 )
2018
9
Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria. ( 29314145 )
2018
10
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 2 - reagent selection and assay optimization for high-sensitivity testing. ( 29236353 )
2018
11
Eculizumab treatment for ischemic enteritis accompanied with paroxysmal nocturnal hemoglobinuria: a case report and literature review. ( 29532162 )
2018
12
Utility of CD157 as a Common Leukocytes Marker for Paroxysmal Nocturnal Hemoglobinuria Screening in a Single Tube Five Color Combination. ( 29622874 )
2018
13
Hereditary Hemochromatosis Manifesting After Treatment of Paroxysmal Nocturnal Hemoglobinuria With Eculizumab. ( 29102415 )
2018
14
Severe Infection of Pseudomonas aeruginosa during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria. ( 29021487 )
2018
15
Introduction to ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria and related disorders. ( 29389086 )
2018
16
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 - clinical utility. ( 29236352 )
2018
17
Risk factors for hemoglobinuria after ultrasonography-guided percutaneous microwave ablation for large hepatic cavernous hemangiomas. ( 29876018 )
2018
18
Concurrent treatment of aplastic anemia/Paroxysmal Nocturnal Hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience. ( 29545341 )
2018
19
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 3 - data analysis, reporting and case studies. ( 29236350 )
2018
20
Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. ( 29749402 )
2018
21
Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs. ( 29721255 )
2018
22
Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. ( 29383624 )
2018
23
Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain Mri Ischemic Lesions In Neurologically Asymtomatic Patients. ( 29323198 )
2018
24
Paroxysmal cold hemoglobinuria with acute renal failure. ( 29853460 )
2018
25
Renal involvement in paroxysmal nocturnal hemoglobinuria: an update on clinical features, pathophysiology and treatment. ( 29486674 )
2018
26
Screening and diagnostic clinical algorithm for paroxysmal nocturnal hemoglobinuria: Expert consensus. ( 29532535 )
2018
27
Correction to: Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. ( 29980910 )
2018
28
ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 4 - assay validation and quality assurance. ( 29251828 )
2018
29
CR1 gene polymorphisms in Chinese patients with paroxysmal nocturnal hemoglobinuria. ( 29551496 )
2018
30
Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. ( 29131151 )
2018
31
Distinct clinical characteristics of paroxysmal nocturnal hemoglobinuria in patients in Southern Taiwan: A multicenter investigation. ( 28811010 )
2017
32
The first case of paroxysmal nocturnal hemoglobinuria and Budd-Chiari syndrome treated with complement inhibitor eculizumab in Korea. ( 28698856 )
2017
33
Renal Manifestations in Paroxysmal Nocturnal Hemoglobinuria. ( 28761231 )
2017
34
T Cell Transcriptomes from Paroxysmal Nocturnal Hemoglobinuria Patients Reveal Novel Signaling Pathways. ( 28630090 )
2017
35
Paroxysmal nocturnal hemoglobinuria with spontaneous clinical remission. ( 28528998 )
2017
36
Acute myeloid leukemia and fatal<i>Scedosporium prolificans</i>sepsis after eculizumab treatment for paroxysmal nocturnal hemoglobinuria: a case report. ( 29359139 )
2017
37
Kids, colds, and complement: paroxysmal cold hemoglobinuria. ( 28594143 )
2017
38
Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report. ( 28328837 )
2017
39
Paroxysmal Nocturnal Hemoglobinuria in the Differential Diagnosis of Thrombocytopenia. ( 28435653 )
2017
40
Renal Biopsy in Paroxysmal Nocturnal Hemoglobinuria: An Insight into the Spectrum of Morphologic Changes. ( 28761230 )
2017
41
Primary Myoglobinuria: Differentiate Myoglobinuria from Hemoglobinuria. ( 28811700 )
2017
42
Paroxysmal cold hemoglobinuria: a difficult diagnosis in adult patients. ( 27807852 )
2017
43
Role of kidney MRI to monitoring clearance of hemosiderin deposits in paroxysmal nocturnal hemoglobinuria. ( 28434706 )
2017
44
Paroxysmal Nocturnal Hemoglobinuria Assessment by Flow Cytometric Analysis. ( 29128072 )
2017
45
Deep sequencing of whole genome exon in paroxysmal nocturnal hemoglobinuria. ( 28124384 )
2017
46
Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry. ( 28748287 )
2017
47
Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. ( 28246555 )
2017
48
Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. ( 29043236 )
2017
49
Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab. ( 28124080 )
2017
50
Cerebral Stroke in a Teenage Girl with Paroxysmal Nocturnal Hemoglobinuria. ( 28626543 )
2017

Variations for Hemoglobinuria

Expression for Hemoglobinuria

Search GEO for disease gene expression data for Hemoglobinuria.

Pathways for Hemoglobinuria

Pathways related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.74 C3 C5 CD14 CD55 CD58 CD59
2
Show member pathways
12.01 C3 CR1 FCGR3B
3 12.01 C3 CD14 CR1 FCGR3B
4 11.91 C3 CD14 FCGR3B
5
Show member pathways
11.82 C3 C5 CD55 CD59 CR1
6
Show member pathways
11.68 C3 C5 CD55 CD59 CR1
7
Show member pathways
11.66 FCGR3B PIGA PIGT PLAUR
8 11.63 C3 CR1 FCGR3B
9 11.61 CD14 CD55 CD59 CR1
10 11.57 C3 C5 CD14
11 11.42 C3 C5 FCGR3B
12 11.39 C3 CD14 CR1
13
Show member pathways
11.38 C3 C5 CD55 CD59 CR1
14 11.31 C3 C5 CD55 CD59 CR1 PLAU
15 11.29 HP PLAU PLAUR
16 11.1 PLAU PLAUR
17 10.65 PLAU PLAUR

GO Terms for Hemoglobinuria

Cellular components related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.98 C3 C5 CD14 CD59 HP PLAU
2 extracellular region GO:0005576 9.97 C3 C5 CD14 CD55 CD59 FCGR3B
3 cell surface GO:0009986 9.8 CD14 CD55 CD58 CD59 CR1 PLAU
4 extracellular exosome GO:0070062 9.73 C3 C5 CD14 CD55 CD58 CD59
5 specific granule membrane GO:0035579 9.58 CD59 PLAU PLAUR
6 secretory granule membrane GO:0030667 9.55 CD14 CD55 CD58 CR1 FCGR3B
7 ficolin-1-rich granule membrane GO:0101003 9.54 CD55 CD58 CR1
8 anchored component of external side of plasma membrane GO:0031362 9.46 CD14 CD59
9 anchored component of membrane GO:0031225 9.17 CD14 CD55 CD58 CD59 FCGR3B PLAUR
10 plasma membrane GO:0005886 10.18 C3 CD14 CD55 CD58 CD59 CR1

Biological processes related to Hemoglobinuria according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.78 C3 C5 CD14 SEMA7A
2 immune system process GO:0002376 9.77 C3 C5 CD14 CD55 CR1
3 blood coagulation GO:0007596 9.72 CD59 PLAU PLAUR
4 innate immune response GO:0045087 9.72 C3 C5 CD14 CD55 CR1
5 chemotaxis GO:0006935 9.7 C5 PLAU PLAUR
6 positive regulation of protein phosphorylation GO:0001934 9.69 C3 PLAUR SEMA7A
7 GPI anchor biosynthetic process GO:0006506 9.54 PIGA PIGT
8 positive regulation of vascular endothelial growth factor production GO:0010575 9.49 C3 C5
9 fibrinolysis GO:0042730 9.46 PLAU PLAUR
10 complement activation, classical pathway GO:0006958 9.46 C3 C5 CD55 CR1
11 positive regulation of interleukin-8 secretion GO:2000484 9.43 CD14 CD58
12 complement activation, alternative pathway GO:0006957 9.4 C3 C5
13 regulation of complement activation GO:0030449 9.35 C3 C5 CD55 CD59 CR1
14 neutrophil degranulation GO:0043312 9.32 C3 CD14 CD55 CD58 CD59 CR1
15 attachment of GPI anchor to protein GO:0016255 9.26 PIGT PLAUR

Molecular functions related to Hemoglobinuria according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 8.92 C3 C5 CD58 PLAUR

Sources for Hemoglobinuria

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....